Work

Dermatofibrosarcoma protuberans (DFSP) with fibrosarcomatous changes in a patient with psoriasis treated with adalimumab

Year: 2015

Type: article

Abstract: adalimumab; dermatofibrosarcoma protuberans; fibrosarcomatous changes; psoriasis.P soriasis is a Th1/Th17 chronic immune- mediated disease, characterized by increased levels of tumor necrosis factor (TNF)-alfa. TNF-alfa blockers including adalimumab have been widely used to treat immune-mediated diseases such as inflammatory bowel disease, psoriasis, rheumatoid arthritis, and psoriatic arthritis.TNF-alfa plays a central role in the inflammation and cellular immune response and TNF inhibitors have all been associated with malignancy and infection, especially when used in combination with other immune suppressants.1 Here we describe a patient with psoriasis treated with adalimumab who developed dermatofibrosarcoma protuberans (DFSP) with fibrosarcomatous change. CASE REPORTA 34-year-old Caucasian man with a history of psoriasis was treated with adalimumab injections, subcutaneous 40 mg every 2 weeks for the past 2 years.The patient was born and raised in New Jersey.He was overweight with a body mass index of 29 but otherwise healthy.His medical history was significant only for psoriasis and removal of an atypical nevus about a decade earlier.HIV antibody serology was negative.

Source: JAAD Case Reports

DOI: 10.1016/j.jdcr.2015.06.007

Authors: Elizaveta A. Belyaeva, Rosalie Elenitsas, Rudolf Roth, Christopher Miller, Joel M. Gelfand

Institutions: Pennsylvania Hospital, University of Pennsylvania

Language: English

Topic: Soft tissue tumor case studies

Subfield: Rheumatology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $750